ChoongChin Liew - BioNexus Gene Chief CoFounder
| BGLC Stock | USD 0.40 0.02 5.26% |
Insider
ChoongChin Liew is Chief CoFounder of BioNexus Gene Lab
| Age | 86 |
| Address | Tower B, Avenue 3, Kuala Lumpur, Malaysia, 59200 |
| Phone | 60 1 307 241 6898 |
| Web | https://www.bionexusgenelab.com |
BioNexus Gene Management Efficiency
The company has return on total asset (ROA) of (0.1011) % which means that it has lost $0.1011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2844) %, meaning that it created substantial loss on money invested by shareholders. BioNexus Gene's management efficiency ratios could be used to measure how well BioNexus Gene manages its routine affairs as well as how well it operates its assets and liabilities. As of February 7, 2025, Return On Tangible Assets is expected to decline to -0.22. The current year's Return On Capital Employed is expected to grow to -0.23. At present, BioNexus Gene's Total Current Assets are projected to increase significantly based on the last few years of reporting.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lynn Smull | Gevo Inc | 64 | |
| Ernest II | Perimeter Solutions SA | 60 | |
| Fabien Jaunault | Givaudan SA ADR | N/A | |
| Paul Guedes | Nano One Materials | N/A | |
| Robert Blum | SenesTech | N/A | |
| Edward Goldberg | Perimeter Solutions SA | 60 | |
| Robert CPA | Orion Engineered Carbons | 65 | |
| AnneMarie Anderson | NewMarket | N/A | |
| CHRP BA | Nano One Materials | N/A | |
| Joel Krutz | Crown Electrokinetics Corp | 51 | |
| Kimberly SPHR | Gevo Inc | 54 | |
| Joshua Ralston | General Environmental Managemen | 33 | |
| Robert Hrivnak | Orion Engineered Carbons | N/A | |
| Srilata Zaheer | H B Fuller | 67 | |
| Yi Paik | Orion Engineered Carbons | 64 | |
| Teresa Rasmussen | H B Fuller | 64 | |
| Steven Krause | SenesTech | 64 | |
| Williams BA | Gevo Inc | 53 | |
| Pamela Kinsman | Nano One Materials | N/A | |
| Timothy Cesarek | Gevo Inc | 60 | |
| Andre Isfort | Orion Engineered Carbons | 44 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.1 |
BioNexus Gene Lab Leadership Team
Elected by the shareholders, the BioNexus Gene's board of directors comprises two types of representatives: BioNexus Gene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNexus. The board's role is to monitor BioNexus Gene's management team and ensure that shareholders' interests are well served. BioNexus Gene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNexus Gene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| SuLeng Tan, Chief Officer | ||
| Sook Yeoh, CEO Director | ||
| Kwan Chan, Marketing Manager | ||
| Too Tham, Managing Director | ||
| Chi Leong, CEO Director | ||
| Wei Leong, CFO Officer | ||
| Yee Wong, President Director | ||
| ChoongChin Liew, Chief CoFounder | ||
| Liong Tan, COO Director |
BioNexus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioNexus Gene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 2.94 M | ||||
| Shares Outstanding | 17.97 M | ||||
| Shares Owned By Insiders | 43.72 % | ||||
| Shares Owned By Institutions | 0.87 % | ||||
| Number Of Shares Shorted | 820.03 K | ||||
| Price To Earning | 350.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.